DexCom, Inc. (NASDAQ:DXCM) EVP Richard Doubleday sold 1,635 shares of the stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $55.53, for a total transaction of $90,791.55. Following the sale, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at $3,612,170.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Richard Doubleday also recently made the following trade(s):

  • On Monday, October 23rd, Richard Doubleday sold 1,635 shares of DexCom stock. The shares were sold at an average price of $44.82, for a total transaction of $73,280.70.

DexCom, Inc. (NASDAQ DXCM) traded up $1.57 during mid-day trading on Thursday, hitting $59.38. 2,337,300 shares of the stock were exchanged, compared to its average volume of 1,435,562. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $88.80. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

Several research firms recently commented on DXCM. BMO Capital Markets reissued an “outperform” rating and set a $62.00 target price (down from $90.00) on shares of DexCom in a research note on Thursday, September 28th. Raymond James Financial lowered shares of DexCom from an “outperform” rating to a “mkt perform” rating in a research note on Friday, September 29th. Canaccord Genuity reissued a “buy” rating and set a $69.00 target price (down from $90.00) on shares of DexCom in a research note on Thursday, September 28th. TheStreet lowered shares of DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. Finally, ValuEngine raised shares of DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and a consensus target price of $70.69.

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock valued at $791,799,000 after acquiring an additional 978,898 shares during the period. Janus Henderson Group PLC increased its stake in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock valued at $431,510,000 after buying an additional 1,991,094 shares during the period. Vanguard Group Inc. increased its stake in DexCom by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock valued at $498,963,000 after buying an additional 224,808 shares during the period. BlackRock Inc. increased its stake in DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock valued at $321,232,000 after buying an additional 230,542 shares during the period. Finally, Brown Advisory Inc. increased its stake in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock valued at $203,798,000 after buying an additional 1,515,134 shares during the period.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: DexCom, Inc. (DXCM) EVP Sells $90,791.55 in Stock” was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.watchlistnews.com/insider-selling-dexcom-inc-dxcm-evp-sells-90791-55-in-stock/1735300.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.